Retatrutide

Overview

Retatrutide (LY3437943) is a novel synthetic peptide that simultaneously activates three incretin and metabolic hormone receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). This triple-agonist mechanism differentiates it from earlier compounds such as semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual), expanding the metabolic regulatory surface area targeted in a single molecule.

By concurrently engaging all three pathways, retatrutide is hypothesized to produce additive effects on appetite suppression, insulin secretion, energy expenditure, and glycemic regulation — making it one of the most active areas of current metabolic research peptide investigation.

Research Highlights

Phase 2 clinical research has reported retatrutide achieving average body weight reductions of up to 24–28% over 48 weeks — outcomes substantially exceeding those observed with GLP-1 monotherapy. Its glucagon receptor agonism is believed to increase energy expenditure, complementing the appetite-reducing effects of the GLP-1 and GIP arms.

Preclinical and early clinical data also suggest beneficial effects on hepatic lipid metabolism, with observations of reduced liver fat in subject populations. Research continues to characterize its full pharmacological profile, particularly the contribution of glucagon receptor engagement to its metabolic outcomes versus what is achievable with dual GLP-1/GIP agents.

For research use only. Not intended for human consumption.

Specifications

Certificate of Analysis

Each batch is independently tested by a third-party laboratory. A Certificate of Analysis (COA) confirming purity and identity is available upon request. Contact us with your order number to receive the COA for your specific lot.